Anti-Payload Antibodies & Panels for ADC PK

	Antibodies
	The latest antibodies news from News Medical

Boost ADC PK research with ACROBiosystems’ high-performance Anti-Payload Antibodies (≥95% purity, high sensitivity/specificity). These antibodies cover key Payloads like MMAE, DXD, and PBD, among over 11 molecules. Each product undergoes rigorous quality control to ensure consistency and minimal cross-reactivity. Antibody Panels feature 2-4 distinct clones for efficient screening.

Explore More Now

			Northwestern team develops antibody to expose hidden pancreatic cancer cells Pancreatic cancer is notoriously hard to treat and often resists the most advanced immunotherapies. Northwestern Medicine scientists have uncovered a novel explanation for that resistance: Pancreatic tumors use a sugar-based disguise to hide from the immune system.

			Rockefeller scientists engineer next-generation antibody to replace IVIG therapy Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions.

	GemPharmatech collaborates with MSK Cancer Center to accelerate discovery of therapeutic antibodies GemPharmatech, a global leader in preclinical research solutions and genetically-engineered mouse models, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the discovery of new therapeutic antibodies.

	Prior exposure to cold viruses boosts antibody response against SARS-CoV-2 Prior exposure to coronaviruses that cause ordinary colds can boost the immune system's ability to attack a vulnerable site on the COVID-19-causing coronavirus SARS-CoV-2, according to a study led by investigators at Weill Cornell Medicine.

	Antibody discovery could provide new treatment options for aggressive breast cancers A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.

	DNA Cassettes Enable Long-Lasting Antibody Production Directly Inside Patients A multidisciplinary team of scientists led by The Wistar Institute, including Perelman School of Medicine at the University of Pennsylvania, AstraZeneca and Inovio Pharmaceuticals, published today in Nature Medicine a breakthrough in biologic antibody production that happens directly in human subjects in this encouraging first clinical trial of its kind.

	Using AI and "Protein Language" Models to Speed Monoclonal Antibody Design Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according to a multi-institutional study led by researchers at Vanderbilt University Medical Center.

How would you rate today's newsletter?

Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2025